Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Curre...

This approval expands the initial Health Canada Notice of Compliance for eosinophilic esophagitis in May 2023 for patients aged...

Under the licensing agreement, Sanofi will be responsible for the global commercialization of AlphaMedix, while Orano Med will ...

Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancer

Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.

Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoin...

Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients ach...

The results were presented today, in collaboration with Regeneron, for the first time at the 2024 European Respiratory Society ...

– License of proprietary masking platform further strengthens Vir's drug discovery capabilities in oncology and infectious ...